Novel drugs lift Sino Biopharm earnings, easing price-cap pain
The pharmaceutical company posted an 11% rise in half-year revenue, helped by growing income from innovative medicines, as it pivots away from the generic drug business Key Takeaways: Revenue from…
Recent Articles
RELATED ARTICLES
-
Unpaid debts, fleeing directors leave Sino-Ocean Group in dire straits
3377.HK -
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
- Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
-
RemeGen hopes for pain relief from expanded drug uses
9995.HK 688331.SHG
-
Akeso marks profit milestone with swift rights issue
9926.HK
